本页面由Tiger Trade Technology Pte. Ltd.提供服务

Innate Pharma SA

1.89
-0.0200-1.05%
盘后1.890.00000.00%17:47 EST
成交量:1.27万
成交额:2.42万
市值:1.74亿
市盈率:-2.94
高:1.96
开:1.88
低:1.88
收:1.91
52周最高:3.51
52周最低:1.43
股本:9,219.65万
流通股本:5,922.40万
量比:0.67
换手率:0.02%
股息:- -
股息率:- -
每股收益(TTM):-0.6440
每股收益(LYR):-0.6319
净资产收益率:-271.37%
总资产收益率:-25.92%
市净率:29.09
市盈率(LYR):-2.99

数据加载中...

2025/05/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/04/30

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/09/11

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/04

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/01/12

SEC问询函

Form CORRESP - Correspondence
2023/04/20

[修订]年度报告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/06

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/12/06

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/10/21

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/04/04

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/07/12

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/05/11

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/04/27

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/16

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/02/12

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/01/27

SEC问询函

CORRESP [Cover] - Correspondence
2020/04/24

年度报告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/14

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/14

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/10

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]